Patients with AAV and kidney involvement who take SGLT-2 inhibitors may have a reduced risk for ESRD and kidney transplant ...

SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from ...

Sean Virani, MD, lead author of the new guidelines and president of the CCS, explained that the guidelines use the term ...

In the treatment of cardiometabolic disease, much has changed in the past 20 years, especially with the emergence of novel ...

Kidney disease is frequently referred to as a “silent” condition because it develops gradually without obvious symptoms.

Deborah J. Wexler, MD, MSc, and colleagues reviewed recent shifts in diabetes care, such as SGLT2i and GLP-1 RA medications.

ON THIS PAGEDiabetes and HydrationCKD and HydrationExpert RecommendationsHydration and MedicationDehydration Warning ...

According to DataM Intelligence, the cardiovascular, renal & metabolic diseases market size reached US$ 298.73 billion in ...

The membranous nephropathy (MN) treatment paradigm is on the brink of transformation, with physicians signaling strong interest in novel mechanisms of action and shifting away from legacy regimens, ...

GLP-1 receptor agonists may have beneficial effects against Alzheimers, psychiatric and addiction disorders, but early data ...